Related references
Note: Only part of the references are listed.Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Androgen pathway resistance in prostate cancer and therapeutic implications
Benjamin L. Maughan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
ShengYu Ku et al.
PLOS ONE (2014)
Hsp90: Still a viable target in prostate cancer
Margaret M. Centenera et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2013)
Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells
Nishant Gandhi et al.
CANCER BIOLOGY & THERAPY (2013)
Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
Yingming Li et al.
CANCER RESEARCH (2013)
NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
Nagalakshmi Nadiminty et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
T. Karantanos et al.
ONCOGENE (2013)
Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression
Ayesha A. Shafi et al.
STEROIDS (2013)
Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors
Joanna L. Gillis et al.
ONCOTARGET (2013)
Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs
Xiangyi Lu et al.
BIOCHEMICAL PHARMACOLOGY (2012)
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
Gopa Iyer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2012)
Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors
Margaret M. Centenera et al.
CLINICAL CANCER RESEARCH (2012)
The AR dependent cell cycle: Mechanisms and cancer relevance
Matthew J. Schiewer et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells
Jeffery D. Eskew et al.
BMC CANCER (2011)
Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression
Yingming Li et al.
CANCER RESEARCH (2011)
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy
Changmeng Cai et al.
ENDOCRINE-RELATED CANCER (2011)
Blockade of testicular and adrenal androgens in prostate cancer treatment
Fernand Labrie
NATURE REVIEWS UROLOGY (2011)
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
Shihua Sun et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors
Ramesh K. Ramanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
Targeting the dynamic HSP90 complex in cancer
Jane Trepel et al.
NATURE REVIEWS CANCER (2010)
Modulation of Hsf1 activity by novobiocin and geldanamycin
Renaud Conde et al.
BIOCHEMISTRY AND CELL BIOLOGY (2009)
A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
Zhiyong Guo et al.
CANCER RESEARCH (2009)
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Qianben Wang et al.
CELL (2009)
ChIP-seq: Using high-throughput sequencing to discover protein-DNA interactions
Dominic Schmidt et al.
METHODS (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis
Suzanne A. Eccles et al.
CANCER RESEARCH (2008)
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Elisabeth I. Heath et al.
CLINICAL CANCER RESEARCH (2008)
Targeting the androgen receptor pathway in prostate cancer
Yu Chen et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Intratumor injection of the hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model
Christopher R. Williams et al.
JOURNAL OF UROLOGY (2007)
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
David B. Solit et al.
CLINICAL CANCER RESEARCH (2007)
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration
Chris J. Tyrrell et al.
BJU INTERNATIONAL (2006)
Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
U Banerji et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence
SL Ettinger et al.
CANCER RESEARCH (2004)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Androgens, lipogenesis and prostate cancer
JV Swinnen et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2004)
The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Luke Whitesell et al.
CURRENT CANCER DRUG TARGETS (2003)
Mechanism of antiandrogen action:: Key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor
V Georget et al.
BIOCHEMISTRY (2002)
Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor
D Masiello et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
Jo Vandesompele et al.
GENOME BIOLOGY (2002)
Share Paper
